Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6451 to 6465 of 8905 results

  1. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  2. Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]

    Discontinued Reference number: GID-TA10698

    Technology appraisal guidance
    Discontinued

  3. Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]

    Discontinued Reference number: GID-TA10702

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]

    Discontinued Reference number: GID-TA10707

    Technology appraisal guidance
    Discontinued

  5. Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]

    Discontinued Reference number: GID-TA10709

    Technology appraisal guidance
    Discontinued

  6. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  7. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Terevalefim for treating delayed graft function after kidney transplant [ID1490]

    Discontinued Reference number: GID-TA11098

    Technology appraisal guidance
    Discontinued

  10. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  11. Ramucirumab for untreated HER2-negative metastatic gastric or gastro-oesophageal junction cancer [ID1373]

    Discontinued Reference number: GID-TA11120

    Technology appraisal guidance
    Discontinued

  12. Bimekizumab for treating active non-radiographic axial spondyloarthritis [ID4010]

    Discontinued Reference number: GID-TA11151

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701

    In development Reference number: GID-TA11157 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Bimekizumab for treating ankylosing spondylitis ID4011

    Discontinued Reference number: GID-TA11171

    Technology appraisal guidance
    Discontinued

  15. Masitinib for treating relapsed or refractory peripheral T-cell non-Hodgkin lymphoma [ID1125]

    Discontinued Reference number: GID-TA11173

    Technology appraisal guidance
    Discontinued